CY1117193T1 - Φαρμακευτικη συνθεση για θεραπεια ή αποτροπη γλαυκωματος - Google Patents
Φαρμακευτικη συνθεση για θεραπεια ή αποτροπη γλαυκωματοςInfo
- Publication number
- CY1117193T1 CY1117193T1 CY20161100125T CY161100125T CY1117193T1 CY 1117193 T1 CY1117193 T1 CY 1117193T1 CY 20161100125 T CY20161100125 T CY 20161100125T CY 161100125 T CY161100125 T CY 161100125T CY 1117193 T1 CY1117193 T1 CY 1117193T1
- Authority
- CY
- Cyprus
- Prior art keywords
- group
- pharmaceutical composition
- substituted
- halogen atom
- glykomat
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- -1 acetic acid compound Chemical class 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/83—Thioacids; Thioesters; Thioamides; Thioimides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Παρεχόμενη είναι μία φαρμακευτική σύνθεση για θεραπεία ή αποτροπή γλαυκώματος, περιλαμβάνουσα ένωση πυριδυλάμινο οξεικό οξύ, που αντιπροσωπεύεται από το γενικό τύπο (I) ή φαρμακολογικώς αποδεκτό άλας αυτού ως δραστικό συστατικό. Στον τύπο (I) τα R1, R2 και R3 έκαστο ανεξαρτήτως αντιπροσωπεύει άτομο υδρογόνου ή τα παρόμοια• Υ αντιπροσωπεύει μία ομάδα: -Q1-Q2 (όπου Q1 αντιπροσωπεύει αρυλένο ομάδα ή τις παρόμοιες• και Q2 αντιπροσωπεύει μία ομάδα όπως ομάδα αρωματικού δακτυλίου η οποία μπορεί να είναι υποκατεστημένη με άτομο αλογόνου ή τα παρόμοια) ή δικυκλικό ετεροαρωματικό δακτύλιο, ο οποίος μπορεί να είναι υποκατεστημένος με ένα άτομο αλογόνου ή τα παρόμοια• και Ζ αντιπροσωπεύει ομάδα όπως αρωματικού δακτυλίου ομάδα, η οποία μπορεί να είναι υποκατεστημένη με άτομο αλογόνου ή τα παρόμοια.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009082725 | 2009-03-30 | ||
EP10758728.9A EP2415763B1 (en) | 2009-03-30 | 2010-03-30 | Pharmaceutical composition for treating or preventing glaucoma |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1117193T1 true CY1117193T1 (el) | 2017-04-05 |
Family
ID=42828246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100125T CY1117193T1 (el) | 2009-03-30 | 2016-02-15 | Φαρμακευτικη συνθεση για θεραπεια ή αποτροπη γλαυκωματος |
Country Status (18)
Country | Link |
---|---|
US (1) | US8685986B2 (el) |
EP (1) | EP2415763B1 (el) |
JP (2) | JP5300033B2 (el) |
KR (1) | KR101681347B1 (el) |
CN (1) | CN102448940B (el) |
AU (1) | AU2010231630B2 (el) |
CA (1) | CA2757291C (el) |
CY (1) | CY1117193T1 (el) |
DK (1) | DK2415763T3 (el) |
ES (1) | ES2564010T3 (el) |
HK (1) | HK1170490A1 (el) |
HR (1) | HRP20160104T1 (el) |
HU (1) | HUE026742T2 (el) |
PL (1) | PL2415763T3 (el) |
PT (1) | PT2415763E (el) |
SI (1) | SI2415763T1 (el) |
SM (1) | SMT201600055B (el) |
WO (1) | WO2010113957A1 (el) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2264009T3 (en) | 2008-03-12 | 2019-04-15 | Ube Industries | PYRIDYLAMINE ACEDIC ACID COMPOUND |
CA2757291C (en) | 2009-03-30 | 2017-05-23 | Ube Industries, Ltd. | Medical composition for treatment or prophylaxis of glaucoma |
JP2011057633A (ja) * | 2009-09-11 | 2011-03-24 | Ube Industries Ltd | ピリジルアミノ酢酸化合物を含有する医薬 |
WO2011030868A1 (ja) * | 2009-09-11 | 2011-03-17 | 宇部興産株式会社 | 置換カルボニル化合物 |
US20120259123A1 (en) | 2009-12-25 | 2012-10-11 | Ube Industries, Ltd. | Aminopyridine compound |
KR102074020B1 (ko) * | 2012-07-13 | 2020-02-05 | 산텐 세이야꾸 가부시키가이샤 | 술폰아미드 화합물의 조합 |
US9339496B2 (en) * | 2012-07-13 | 2016-05-17 | Santen Pharmaceutical Co., Ltd. | Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist |
JPWO2014157672A1 (ja) | 2013-03-28 | 2017-02-16 | 宇部興産株式会社 | 置換ビアリール化合物 |
AU2015205179B2 (en) | 2014-01-10 | 2019-09-19 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical composition containing pyridylamino acetic acid compound |
EP3750541A1 (en) * | 2014-01-10 | 2020-12-16 | Santen Pharmaceutical Co., Ltd | Pharmaceutical preparation containing pyridylaminoacetic acid compound |
KR101858373B1 (ko) * | 2014-01-10 | 2018-05-15 | 산텐 세이야꾸 가부시키가이샤 | 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물 |
US10519112B2 (en) | 2014-06-10 | 2019-12-31 | Ube Industries, Ltd. | Method for producing heteroaromatic sulfonamide compound |
US10428046B2 (en) * | 2014-06-10 | 2019-10-01 | Ube Industries, Ltd. | N-substituted sulfonamide compound and method for producing same |
US10774072B2 (en) | 2014-06-10 | 2020-09-15 | Ube Industries, Ltd. | Crystal of N-substituted sulfonamide compound |
JP2017206445A (ja) * | 2014-09-26 | 2017-11-24 | 宇部興産株式会社 | 呼吸器疾患の治療及び/又は予防のための医薬組成物 |
AR105215A1 (es) * | 2015-07-01 | 2017-09-13 | Santen Pharmaceutical Co Ltd | Formulación de depósito que contiene ésteres de ácido cítrico |
JP7032134B2 (ja) * | 2015-07-09 | 2022-03-08 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物を含有する予防及び/又は治療剤 |
WO2019065838A1 (ja) | 2017-09-29 | 2019-04-04 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物を含有する医薬 |
EP3730143A4 (en) | 2017-12-21 | 2021-08-18 | Santen Pharmaceutical Co., Ltd. | OMIDENEPAG COMBINATION |
TWI833535B (zh) | 2017-12-21 | 2024-02-21 | 日商參天製藥股份有限公司 | 賽佩普斯特(Sepetaprost)及Rho激酶抑制劑之組合醫藥 |
US11666563B2 (en) * | 2017-12-28 | 2023-06-06 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical preparation containing pyridyl aminoacetic acid compound |
KR20220089106A (ko) | 2020-12-21 | 2022-06-28 | 이성규 | 도르졸라마이드 또는 폴리소르베이트80을 유효성분으로 포함하는 점안용 조성물 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
UA67754C2 (uk) | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
EP1051176B1 (en) | 1998-01-27 | 2006-11-22 | Aventis Pharmaceuticals Inc. | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS |
WO2002024647A1 (fr) | 2000-09-21 | 2002-03-28 | Ono Pharmaceutical Co., Ltd. | Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine |
KR20040022238A (ko) | 2001-08-09 | 2004-03-11 | 오노 야꾸힝 고교 가부시키가이샤 | 카르복실산 유도체 화합물 및 그 화합물을 유효성분으로서 함유하는 약제 |
ES2259010T3 (es) | 2001-10-26 | 2006-09-16 | Allergan, Inc. | Analogos de omega-cicloalquil-17-heteroaril-prostaglandina e2 como agonistas del receptor ep2. |
WO2003064391A1 (en) | 2002-01-31 | 2003-08-07 | Pfizer Products Inc. | Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid |
WO2003074483A1 (fr) | 2002-03-05 | 2003-09-12 | Ono Pharmaceutical Co., Ltd. | Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif |
US20070000939A1 (en) | 2002-10-29 | 2007-01-04 | Vasilios Vasiadis | Device for handling and orientating pills or tablets in a precise manner |
BRPI0408061A (pt) * | 2003-03-04 | 2006-02-14 | Pfizer Prod Inc | tratamento médico utilizando um agonista de receptores seletivos de ep 2 |
GB0329620D0 (en) | 2003-12-22 | 2004-01-28 | Pharmagene Lab Ltd | EP2 receptor agonists |
JP2007186424A (ja) | 2004-11-26 | 2007-07-26 | Ono Pharmaceut Co Ltd | 気管支拡張剤 |
WO2005072743A1 (ja) | 2004-01-30 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | 気管支拡張剤 |
EP1714961B1 (en) | 2004-02-12 | 2015-12-09 | Mitsubishi Tanabe Pharma Corporation | Indazole compound and pharmaceutical use thereof |
EP1593671A1 (en) | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV inhibitors |
EP1765332A2 (en) | 2004-06-17 | 2007-03-28 | Cengent Therapeutics, Inc. | Trisubstituted nitrogen modulators of tyrosine phosphatases |
GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
WO2006074884A1 (en) | 2005-01-14 | 2006-07-20 | F.Hoffmann-La Roche Ag | Thiazole-4-carboxamide derivatives as mglur5 antagonists |
JP4874958B2 (ja) | 2005-03-30 | 2012-02-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピリジン誘導体を含有する抗真菌剤 |
EP1912957A4 (en) | 2005-08-03 | 2009-05-13 | Merck Frosst Canada Ltd | EP4 AGONIST RECEIVER, COMPOSITIONS AND METHODS RESULTING THEREFROM |
EP1951701A2 (en) | 2005-08-09 | 2008-08-06 | Asterand Uk Limited | Ep2 receptor agonists |
US7696235B2 (en) | 2005-08-29 | 2010-04-13 | Allergan, Inc. | EP2 receptor agonists for treating glaucoma |
EA200970067A1 (ru) | 2006-07-28 | 2009-08-28 | Пфайзер Продактс Инк. | Агонисты ep2 |
FI123744B (fi) * | 2006-09-06 | 2013-10-15 | Sandvik Mining & Constr Oy | Menetelmä kallion poraamiseksi |
DK2264009T3 (en) | 2008-03-12 | 2019-04-15 | Ube Industries | PYRIDYLAMINE ACEDIC ACID COMPOUND |
CA2757291C (en) | 2009-03-30 | 2017-05-23 | Ube Industries, Ltd. | Medical composition for treatment or prophylaxis of glaucoma |
-
2010
- 2010-03-30 CA CA2757291A patent/CA2757291C/en active Active
- 2010-03-30 WO PCT/JP2010/055719 patent/WO2010113957A1/ja active Application Filing
- 2010-03-30 AU AU2010231630A patent/AU2010231630B2/en active Active
- 2010-03-30 PL PL10758728T patent/PL2415763T3/pl unknown
- 2010-03-30 CN CN201080023601.4A patent/CN102448940B/zh active Active
- 2010-03-30 KR KR1020117025638A patent/KR101681347B1/ko active IP Right Grant
- 2010-03-30 US US13/260,946 patent/US8685986B2/en active Active
- 2010-03-30 PT PT107587289T patent/PT2415763E/pt unknown
- 2010-03-30 EP EP10758728.9A patent/EP2415763B1/en active Active
- 2010-03-30 JP JP2011507220A patent/JP5300033B2/ja active Active
- 2010-03-30 HU HUE10758728A patent/HUE026742T2/en unknown
- 2010-03-30 DK DK10758728.9T patent/DK2415763T3/en active
- 2010-03-30 ES ES10758728.9T patent/ES2564010T3/es active Active
- 2010-03-30 SI SI201031130A patent/SI2415763T1/sl unknown
-
2012
- 2012-11-09 HK HK12111327.7A patent/HK1170490A1/zh unknown
-
2013
- 2013-04-08 JP JP2013080307A patent/JP5556924B2/ja active Active
-
2016
- 2016-01-29 HR HRP20160104T patent/HRP20160104T1/hr unknown
- 2016-02-15 CY CY20161100125T patent/CY1117193T1/el unknown
- 2016-02-24 SM SM201600055T patent/SMT201600055B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP5300033B2 (ja) | 2013-09-25 |
US8685986B2 (en) | 2014-04-01 |
AU2010231630B2 (en) | 2015-02-12 |
AU2010231630A1 (en) | 2011-11-10 |
CA2757291C (en) | 2017-05-23 |
HRP20160104T1 (hr) | 2016-03-25 |
EP2415763B1 (en) | 2016-01-27 |
HUE026742T2 (en) | 2016-07-28 |
PT2415763E (pt) | 2016-03-30 |
EP2415763A4 (en) | 2012-08-15 |
JPWO2010113957A1 (ja) | 2012-10-11 |
SMT201600055B (it) | 2016-04-29 |
KR101681347B1 (ko) | 2016-11-30 |
HK1170490A1 (zh) | 2013-03-01 |
EP2415763A1 (en) | 2012-02-08 |
JP2013151548A (ja) | 2013-08-08 |
ES2564010T3 (es) | 2016-03-17 |
CA2757291A1 (en) | 2010-10-07 |
WO2010113957A1 (ja) | 2010-10-07 |
DK2415763T3 (en) | 2016-03-07 |
PL2415763T3 (pl) | 2016-05-31 |
SI2415763T1 (sl) | 2016-05-31 |
US20120190852A1 (en) | 2012-07-26 |
CN102448940A (zh) | 2012-05-09 |
JP5556924B2 (ja) | 2014-07-23 |
KR20120003475A (ko) | 2012-01-10 |
CN102448940B (zh) | 2015-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117193T1 (el) | Φαρμακευτικη συνθεση για θεραπεια ή αποτροπη γλαυκωματος | |
CY1123237T1 (el) | Αρυλο και ετεροαρυλο συμπυκνωμενες λακταμες | |
CY1120073T1 (el) | Παραγωγα πυραζολο-αμινοπυριμιδινης ως ρυθμιστες της lrrk2 | |
CY1124582T1 (el) | Μεθοδος παραγωγης ενωσεων που εχουν δρασης αναστολης ιντεγκρασης hiv | |
CY1119655T1 (el) | Παραγωγα 5-φαινοξυ-3η-πυριμιδιν-4-ονης και η χρηση αυτων ως αναστολεων αναστροφης μεταγραφασης hiv | |
CY1115227T1 (el) | Νεοι καταστολεις φωσφοδιεστερασης (phosphodiesterase) | |
CY1124173T1 (el) | Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες | |
AU2011274192A8 (en) | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof | |
CY1118135T1 (el) | Παραγωγα 2-(φαινυλο ή πυριδ-3-υλο) αμινοπυριμιδινης ως ρυθμιστες κινασης lrrk2 για τη θεραπευτικη αντιμετωπιση της νοσου του parkinson | |
CY1118129T1 (el) | 5-αλκυνυλ-πυριμιδινες | |
CY1120127T1 (el) | Παραγωγο πυριδινης | |
CY1117197T1 (el) | Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ | |
EA201000946A1 (ru) | Бициклические производные для применения при лечении состояний, связанных с андрогенным рецептором | |
CY1119220T1 (el) | Μονοκυκλικο παραγωγο πυριδινης | |
MX2012002759A (es) | Compuestos quimicos. | |
CY1120420T1 (el) | Παραγωγα σουλφονυλοπιπεριδινης και χρηση αυτων πα την αγωγη νοσων με τη μεσολαβηση προκινετισινης | |
PE20090556A1 (es) | DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO [1,2-b]-PIRIDAZINA COMO INHIBIDORES DE CASEINA QUINASAS Y SU PREPARACION | |
CU20110083A7 (es) | Compuestos heteroaromáticos espirocíclicos fusionados para el tratamiento de infecciones bacterianas | |
UA109525C2 (xx) | Алкіламідна сполука і її застосування | |
MX336071B (es) | Formulaciones intravenosas de antagonistas de neurocinina 1. | |
EA201790923A1 (ru) | Производные бетулина | |
MX2018008095A (es) | Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih. | |
MX2012006026A (es) | Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus. | |
CY1119118T1 (el) | Θεραπευτικος παραγων για τις διαταραχες της διαθεσης | |
DK2997033T3 (da) | Kondenserede tricykliske heterocykliske forbindelser som hiv- integrasehæmmere |